Graham M L, Krett N L, Miller L A, Leslie K K, Gordon D F, Wood W M, Wei L L, Horwitz K B
Department of Medicine, University of Colorado Health Sciences Center, Denver 80262.
Cancer Res. 1990 Oct 1;50(19):6208-17.
We postulate that one mechanism for the progression of breast cancers to hormone resistance involves the acquisition of mutant estrogen receptors (ER)4 by genetically unstable cell subpopulations. The T47D human breast cancer cell line may be a model for such progression, having sublines that are ER positive and estrogen responsive, ER positive and estrogen resistant, or ER negative. Also, T47D cells can be either hyperdiploid (HD) or hypertetraploid (HT) or persistently alternate between these states. T47DCO cells are a HD and ER-positive, but estrogen-resistant, subline of T47D cells that undergoes spontaneous tetraploidization. Such a stable variant, designated T47Dv, is 85% HT (Cancer Res., 49: 3943, 1989). We now show that single-cell clones derived from the mixed HD/HT T47Dv can be either HD or HT, and can be either estrogen responsive or estrogen resistant, for growth and for progesterone receptor regulation. To begin the study of ER in this model system of T47DCO and their derivatives, we have generated complementary DNA libraries from the parental HD T47DCO cells and have isolated three ER complementary DNA mutants. These include two frame-shift/termination mutants that would encode ERs truncated in the DNA-binding domain and in the hormone-binding domain and a third mutant with a large in-frame deletion spanning the hinge region and a part of the hormone-binding domain. If expressed, these mutant ERs would lack hormone-binding capacity and would be undetected by the anti-ER antibodies currently in clinical use. Genetic instability, when associated with mutant ERs in subpopulations of breast tumor cells, may provide the selective pressure leading to hormone resistance. T47DCO cells and their clonal derivatives provide a model for the systematic study of ER mutations and other mechanisms of hormone resistance in Stage IV breast cancer.
我们推测,乳腺癌发展为激素抵抗的一种机制涉及基因不稳定的细胞亚群获得突变的雌激素受体(ER)4。T47D人乳腺癌细胞系可能是这种进展的一个模型,它有ER阳性且对雌激素有反应、ER阳性且对雌激素抵抗或ER阴性的亚系。此外,T47D细胞可以是超二倍体(HD)或超四倍体(HT),或者在这些状态之间持续交替。T47DCO细胞是T47D细胞的一个HD且ER阳性但对雌激素抵抗的亚系,它会自发四倍体化。这样一个稳定的变体,命名为T47Dv,85%是HT(《癌症研究》,49: 3943, 1989)。我们现在表明,从混合的HD/HT T47Dv衍生的单细胞克隆可以是HD或HT,并且在生长和孕激素受体调节方面可以是雌激素反应性的或雌激素抵抗性的。为了在这个T47DCO及其衍生物的模型系统中开始对ER的研究,我们从亲本HD T47DCO细胞生成了互补DNA文库,并分离出三个ER互补DNA突变体。这些包括两个移码/终止突变体,它们编码在DNA结合域和激素结合域中被截断的ER,以及第三个突变体,其在框内有一个大的缺失,跨越铰链区和部分激素结合域。如果表达,这些突变的ER将缺乏激素结合能力,并且目前临床使用的抗ER抗体将检测不到它们。当与乳腺肿瘤细胞亚群中的突变ER相关联时,基因不稳定可能提供导致激素抵抗的选择压力。T47DCO细胞及其克隆衍生物为系统研究IV期乳腺癌中ER突变和其他激素抵抗机制提供了一个模型。